T: +44 (0)114 222 2261
The University of Sheffield with Sheffield Teaching Hospitals NHS Foundation Trust is the only site in the UK to have participated in an international clinical trial for an investigational drug in people with a form of motor neurone disease (MND)
Neuroscience research at the University of Sheffield has been recognised by Her Majesty The Queen for delivering real benefits in improving patient outcomes for people living with some of the most devastating neurodegenerative diseases.
The Sheffield Institute for Translational Neuroscience (SITraN) based at the University of Sheffield was awarded a Queen’s Anniversary Prize today (21 November 2019) at St James’s Palace.
The prize awarded to SITraN is unique in the honours system and only bestowed upon a UK college or university which demonstrates new and innovative approaches to its research and development that have delivered benefits to the public at local, national and global levels.
SITraN’s vision is to harness the rapidly emerging, exciting developments in neuroscience to translate into new treatments and improved quality of life for patients with neurodegenerative disorders such as Parkinson’s Disease, Motor Neurone Disease (MND), Dementia and Alzheimer’s Disease and Multiple Sclerosis (MS).
Achievements highlighted by the award include:
Professor Dame Pamela Shaw, Director of SITraN, said: “Receiving this award is a great honour. It gives recognition to our research teams who have made enormous scientific progress in treating some of the most devastating neurological diseases, making a real difference to patients’ lives.
“We hope that this award will inspire confidence for patients and their families, research partners and donors as we continue to make discoveries that deepen the understanding of neurological diseases and open up the potential for new treatments and therapies.”
SITraN – which will celebrate its 10th anniversary in 2020 – is considered a world-leader in neuroscience research. Its work forms part of the University of Sheffield’s Neuroscience Institute, which aims to bring academics together from across varied specialties to translate scientific discoveries from the lab into pioneering treatments that will benefit people living with neurodegenerative diseases.
Professor Koen Lamberts, President and Vice-Chancellor of the University of Sheffield, said: “It’s wonderful to see the Queen’s Anniversary Award recognising the University of Sheffield as a centre for excellence in neuroscience research and teaching which has the power to transform people’s lives.
“As well as making life-changing discoveries today, SITraN is nurturing the next generation of talented neuroscience students, whose research will lead to pioneering treatments for those living with neurological diseases in the future.”
Chair of the Royal Anniversary Trust, Sir Damon Buffini, said: “The prizes are granted every two years by the Queen and are the most prestigious national honour awarded to UK universities and colleges for their work.
“Entries in the scheme are invited in any subject area and are subjected to rigorous independent assessment in a process managed by the Royal Anniversary Trust. Recommendations for the Queen’s approval are made on the Prime Minister’s advice.
“The criteria are demanding and look for outstanding excellence in the chosen field, for innovation and for evidence of real public benefit. Competition is strong and the award is a mark of high quality in education and training which is widely recognised internationally as well as in the UK.”
Dr Hautbergue joined the Sheffield Institute for Translational Neuroscience (SITraN) in August 2012 to set up a specialist laboratory for RNA Molecular Biology. His area of research and teaching focuses on the investigation of gene expression in physiological and neurodegenerative diseases with a particular research focus on motor neurone disease (MND).
Research in his group aims at identifying dysregulated gene expression events that cause incurable neurodegenerative conditions such as MND in order to correct these using gene therapy approaches.
Dr Hautbergue and colleagues showed for the first time that manipulating a cellular process involved in the transport of RNA molecules across nuclear pores confers a novel potential promising strategy of neuroprotection for the most common form of MND.
Throughout his career, Dr Hautbergue has had a variety of roles across the RNA field which have allowed him to become an advisor to students and colleagues on translational and RNA biology experiments. As an elected member of the Royal Society of Biology, Dr Hautbergue will also contribute to policy making, strategy and influence developments in science within the Royal Society of Biology.
Having grown up in a small village in Burgundy in rural France, Dr Hautbergue developed an interest in the biology behind things from an early age. He said: “From the age of 12, I became so fascinated by biology that for my 14th birthday, I had built with my father a lab bench in my bedroom. It was great and pleased everyone at home as I used to perform experiments with chemicals as well as microscopic observations with insects or small animals on the kitchen dining table.”
On being elected as a Fellow of the Royal Society of Biology, Dr Hautbergue said: “It is a great honour and privilege to have been invited to become a Fellow of the Royal Society of Biology (FRSB) following a nomination and a review process that was unknown to me.”
“Being recognised by others I don’t know, but who have judged the research I carry with passion as a prominent contribution to the advancement of biological sciences is an incredible feeling at this stage of my career. It is difficult to find words. It is with great excitement and enthusiasm that I will engage with the other members of the Royal Society of Biology.”
Dr Hautbergue added: “None of this would have been possible without the excellent researchers that are surrounding me, both junior and senior, as well as all of the technical and professional teams that support our work. I would like to thank all of them for the inspiring research and teaching atmosphere they create in the Department of Neuroscience.
"In particular, I express my deepest acknowledgements to Dr Lydia Castelli and Dr Ya-Hui (Erica) Lin who are talented postdoctoral researchers in my team and to the fantastic collaborators I feel lucky to routinely work with. These include Prof Dame Pamela Shaw, Prof Mimoun Azzouz, Dr Laura Ferraiuolo, Dr Alex Withworth, Dr Marta Milo and Dr Tennore Ramesh. I am also immensely grateful to the patrons that support our Institute and the patients with MND who kindly provide biosamples which are essential to our research.”
Being part of the Royal Society of Biology means that Dr Hautbergue joins a community of over 17,500 leading minds that make up the diverse membership of individuals and organisations from across the world.
Read more about Dr Hautbergue’s achievements and experiences here
Dr Laura Ferraiuolo, from the Department of Neuroscience and Sheffield Institute of Translational Neuroscience (SITraN), has achieved international recognition for her work to investigate the causes and treatment of motor neurone disease (MND).
Dr Ferraiuolo has been awarded the 11th Paulo Gontijo Award in recognition of her work on the contribution of glial cells in the development of amyotrophic lateral sclerosis (ALS) and their importance as a therapeutic target. The award was judged rigorously by the jury committee of the Paulo Gontijo Institute (IPG), composed of five researchers recognised by the international scientific community.Institute of Translational Neuroscience (SITraN), has achieved international recognition for her work to investigate the causes and treatment of motor neurone disease (MND).
Established in 2007, the Paulo Gontijo Award recognises young researchers below 40 years of age who have dedicated their scientific work to investigate the causes and treatment of motor neuron disease.
Dr Ferraiuolo is a Reader in Translational Neurobiology, the work of her research group has demonstrated that glia play an active role in neuronal degeneration. Her lab uses various in vitro cell models, including primary cells and genetically reprogrammed human progenitor cells, to investigate the interaction between astrocytes and oligodendrocytes from patients affected by MND with neurons.
Dr Ferraiuolo said: "I am grateful to the patients affected by MND who are at the centre of my research efforts and a constant motivation to work hard to find new therapeutic approaches for this devastating disease. Being recognised for the work I have carried out over the years with my team, amongst inspiring leading scientists in the field who have previously received the Paulo Gontijo award is a great honour. I am lucky to be surrounded by excellent scientists at SITraN, all driven to unravel the complex processes leading to neurodegeneration".
The award ceremony will take place in December 2019 during the opening of the International Symposium on ALS/MND in Perth, Australia, where Dr Ferraiuolo will present her winning paper to the scientific community.
A drug which has been used to treat liver disease for over 30 years is being trialled in patients with Parkinson’s Disease to determine its safety and tolerability in Parkinson’s, but also to assess its potential to slow down disease progression for the first time.
The ground-breaking study, led by researchers at the University of Sheffield in partnership with Sheffield Teaching Hospitals NHS Foundation Trust, will assess the safety and tolerability of the liver drug ursodeoxycholic acid (UDCA) in Parkinson’s patients – a drug which is hoped could potentially be repositioned to help slow down the progression of the disease.
Parkinson’s Disease currently affects around 145,000 people in the UK. The progressive neurological condition severely affects a patient’s quality of life and symptoms include problems with mobility such as walking, coordination or tremor, but can also result in memory loss, low mood or abnormal bowel function.
The symptoms of Parkinson’s are mainly due to the loss of dopamine containing nerve cells in the area of the brain which controls movement. An important reason why these cells die in the brain of patients with Parkinsons is due to a malfunction of the cell’s batteries – known as mitochondria.
The trial, led by Oliver Bandmann, Professor of Movement Disorders Neurology at the Sheffield Insitute for Translational Neuroscience (SITraN) and also an Honorary Consultant Neurologist at Sheffield Teaching Hospitals NHS Foundation Trust, was made possible due to the NIHR Sheffield Biomedical Research Centre (BRC) for Neurological Disorders.
Professor Bandmann and his team previously identified UDCA as the most promising drug to rescue mitochondrial function in Parkinson’s in a drug screen where 2,000 drugs were assessed for their rescue effect on mitochondrial function directly in the tissue of patients with Parkinson’s.
“After nearly a decade of research we are extremely pleased to launch the first clinical trial of UDCA in Parkinson’s patients to see if the drug is safe and tolerated,” said Professor Bandmann.
“This is a pilot trial, which if successful, will lead to a bigger study to firmly establish the effectiveness of the treatment to slow down progression of Parkinson’s. Currently, Parkinson’s is relentlessly progressive but patients tend to respond very well to symptomatic medication in the early stages of the disease.
“A drug which will slow down the progression of the disease – even after the first few years of diagnosis – would help people to have an improved quality of life for longer.”
The trial, known as the UP Study (UDCA in Parkinson’s) will be conducted at two centres in the UK, Sheffield and London, in collaboration with Professor Tom Foltynie at University College London Hospitals. Working in collaboration with researchers from the University of Sheffield’s Institute for Insilico Medicine (Insigneo), the NIHR Sheffield Clinical Research Facility at Sheffield Teaching Hospitals and the NIHR Sheffield Biomedical Research Centre, the effectiveness of the drug will be assessed with two novel approaches:
The clinical trial is supported by the JP Moulton Charitable Foundation, The Cure Parkinson’s Trust and the pharmaceutical company PRO.MED.CS.
Helen Matthews, Deputy Chief Executive Officer of The Cure Parkinson’s Trust said: “Through its International Linked Clinical Trials Programme, The Cure Parkinson’s Trust has been working towards bringing UDCA into clinical trials - and this trial is the first step in understanding the drug’s potential to slow Parkinson’s progression. We are delighted to be supporting Professor Bandmann’s important work.”